A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IO-PAZ
- Sponsors Novartis Pharmaceuticals
- 30 Jun 2017 Planned End Date changed from 19 Aug 2020 to 2 Sep 2020.
- 30 Jun 2017 Planned primary completion date changed from 19 Aug 2020 to 2 Sep 2020.
- 29 Jun 2017 New trial record